Overview

A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Claritin® Tablets 24-Hour in Subjects With Allergic Conjunctivitis

Status:
Recruiting

Trial end date:
2022-04-01

Target enrollment:

Participant gender:

Summary

This is a single-center, randomized, double-masked, parallel study. In this clinical study, the efficacy comparison between Pataday® Once Daily Relief Extra Strength and Claritin® Tablets 24-Hour will be made using the Ora-CAC model, a validated clinical model accepted by regulatory agents for assessing the efficacy of products on the signs and symptoms of allergic conjunctivitis.

Phase:

Phase 4

Details

Lead Sponsor:

Andover Research Eye Institute

Treatments:

Dextrans
Loratadine
Olopatadine Hydrochloride
Ophthalmic Solutions